Different types of centrally acting antihypertensives and their targets in the central nervous system

Cardiovascular Drugs and Therapy

Volumn 8, Issue 6, 1994, Pages 787-799

  van Zwieten, P A ^a   Chalmers, J P ^b  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b FLINDERS MEDICAL CENTRE   (Australia)

Author keywords

centrally acting antihypertensives; imidazoline receptors; moxonidine; rilmenidine; serotonergic pathways

Indexed keywords

1 ISOPROPYL 6 METHYLERGOLINE 8 CARBOXYLIC ACID 2 HYDROXY 1 METHYLPROPYL ESTER; 4 AMINOBUTYRIC ACID; 5,7 DIHYDROXYTRYPTAMINE; ACETYLCHOLINE; ALPHA 2 ADRENERGIC RECEPTOR; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; ALPHA METHYLDOPAMINE; ANTIHYPERTENSIVE AGENT; CLONIDINE; CORBADRINE; ENKEPHALIN; EXCITATORY AMINO ACID; FLESINOXAN; GLUTAMIC ACID; GUANFACINE; IDAZOXAN; IMIDAZOLINE RECEPTOR; KETANSERIN; METHYLDOPA; MOXONIDINE; NEUROPEPTIDE Y; OXIDOPAMINE; PRAZOSIN; RAUWOLSCINE; RILMENIDINE; RITANSERIN; SEROTONIN; SEROTONIN 1A RECEPTOR; SEROTONIN AGONIST; SOMATOSTATIN; SUBSTANCE P; UNINDEXED DRUG; YOHIMBINE;

DRUG STRUCTURE; FATIGUE; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; IMPOTENCE; MEDULLA OBLONGATA; NEUROPHARMACOLOGY; NONHUMAN; ORTHOSTATIC HYPOTENSION; PRESSORECEPTOR REFLEX; PRIORITY JOURNAL; REVIEW; SEDATION; SYMPATHETIC BLOCKING; XEROSTOMIA;

ANIMAL; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CENTRAL NERVOUS SYSTEM; HUMAN;

EID: 0028643651     PISSN: 09203206     EISSN: 15737241     Source Type: Journal    
DOI: 10.1007/BF00877397     Document Type: Review

References (64)

1. Brainstem and bulbospinal neurotransmitter systems in the control of blood pressure
2. Amino acid neurotransmitters in the central control of blood pressure and in experimental hypertension
3. Brain amines and models of experimental hypertension
4. Immunohistochemical evidence for the existence of adrenaline neurons in the rat brain
5. Peptidergic neurons
6. Amino acid neurotransmitters in hypertension
7. Separate areas of rat medulla oblongata with populations of serotonin- and adrenaline-containing neurons alter blood pressure after L-glutamate stimulation
8. Subregions of rostral ventral medulla control arterial pressure and regional hemodynamics
9. The affect of intrathecal serotonergic antagonists on the pressor response to stimulation of the brainstem in the rat
10. Central serotonergic mechanisms in cardiovascular regulation
11. Bulbospinal serotonin neurons and hypotensive effects of methyldopa in the spontaneously hypertensive rat
12. Differences in the central hypotensive actions of methyldopa and clonidine in the spontaneously hypertensive rat: Contribution of neurons arising from the B3 and the C1 areas of the rostral ventrolateral medulla
13. Different types of centrally acting antihypertensive drugs
14. Central serotonergic mechanisms in hypertension
15. Is L-glutamate a neurotransmitter of baroreceptor information in the nucleus of the tractus solitarius?
16. Evidence for an excitatory amino acid pathway in the brainstem and for its involvement in cardiovascular control
17. Aortic baroreceptor reflexes are mediated by NMDA receptors in caudal ventrolateral medulla
18. Inhibitory cardiovascular function of neurons in the caudal ventrolateral medulla of the rabbit: Relationship to the area containing A1 noradrenergic cells
19. Glutamate in spinally projecting neurons of the rostral ventral medulla
20. Glutamate in the spinal sympathetic intermediolateral nucleus: Localization by light and electron microscopy
21. Glutamate-immunoreactive synapses on retrogradely-labelled sympathetic preganglionic neurons in rat spinal cord
22. Centrally acting drugs
23. Actions des alpha-sympathomimétiques sur les structures nerveuses
24. Cardiac hypertrophy and antihypertensive therapy
25. α-methyl-DOPA and related compounds
26. Abrupt cessation of clonidine administration: A prospective study
27. The classification of antihypertensive drugs
28. The pharmacological base of the hypotensive activity and side-effects of alpha-methyl-DOPA, clonidine and guanfacine
29. Overview of α2-adrenoceptor agonists with a central action
30. The hypotensive activity and side-effects of methyldopa, clonidine and guanfacine
31. Regional vascular effects of serotonin and ketanserin in young healthy subjects
32. α1-And α2-adrenoceptor-mediated vasoconstriction in the forearm of normotensive and hypertensive subjects
33. Pharmacological activity of the isomers of LY 52587, a potent and selective 5-HT2-receptor antagonist
34. The acute and chronic antihypertensive effects of ketanserin cannot be explained by blockade of vascular serotonin, type 2, receptors or α-adrenergic receptors
35. Serotonergic receptors and drugs in hypertension
36. Involvement of brain 5-HT1A-receptors in the hypotensive response to urapidil
37. Urapidil and some analogs with high affinities for serontonin1A and α1-adrenoceptor binding sites show potent hypotensive activity upon central administration
38. The mechanism of the sympathoinhibitory action of urapidil: Role of 5-HT1A-receptors
39. Central 5-HT1A-receptors and the mechanism of the central hypotensive effect of (+)8-OH-DPAT, DP-5-CT, R 28935 and urapidil
40. Comparison of the cardiovascular effects of the 5-HT1A-receptor agonist flesinoxan with that of 8-OH-DPAT in the rat
41. Urapidil
42. Central hypotensive activity of ketanserin in cats
43. Experimental studies on the neurocardiovascular effect of urapidil
44. Cardiovascular response to 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) in the rat: Site of action and pharmacological analysis
45. Urapidil and some analogues with hypotensive properties show high affinities for 5-hydroxy-tryptamine (5HT) binding sites of the 5-HT1A-subtype and for α1-adrenoceptor binding sites
46. Effects of serotonin, receptor agonists and antagonists on blood pressure, heart rate and sympathetic nerve activity
47. Urapidil, a multiple action α-blocking drug
48. International symposium on urapidil
49. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the treatment of hypertension
50. Vascular effects of ketanserin (R 42468), a novel antagonist at 5-HT2-serotonergic receptors
51. A possible central action of prazosin and ketanserin to cause hypertension
52. Central hypotensive activity of ketanserin in cats
53. Ageing, serotonin and ketanserin
54. The serotonin antagonist ketanserin in the treatment of clinical hypertension: A short review
55. Keeping an eye on the I site: Imidazoline-preferring receptors
56. Rilmenidine lowers arterial pressure via imidazole receptors in brain stem C1 area
57. Importance of imidazoline receptors in the cardiovascular response to clonidine and rilmenidine in conscious rabbits
58. An imidazoline-specific mechanism for the hypotensive effect of clonidine: A study with yohimbine and idazoxan
59. Rilmenidine in mild to moderate hypertension. A double-blind, randomised, parallel group multicenter comparison with methyldopa in 157 patients
60. Clinical pharmacology of imidazolines and related compounds
61. From α2-adrenoceptors to imidazoline preferring receptors
62. A second generation of centrally acting antihypertensives acts on putative I1-imidazoline receptors
63. Moxonidine